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Abstract
Background: People with inflammatory rheumatological conditions such as rheumatoid arthritis, psoriatic arthritis,
ankylosing spondylitis, polymyalgia rheumatica and giant cell arteritis are at an increased risk of common
comorbidities including cardiovascular disease, osteoporosis and mood problems, leading to increased morbidity
and mortality. Identifying and treating these problems could lead to improved patient quality of life and outcomes.
Despite these risks being well-established, patients currently are not systematically targeted for management
interventions for these morbidities. This study aimed to assess the feasibility of conducting a randomised controlled
trial (RCT) of a nurse-led integrated care review in primary care to identify and manage these morbidities.
Methods: A pilot cluster RCT was delivered across four UK general practices. Patients with a diagnostic Read code
for one of the inflammatory rheumatological conditions of interest were recruited by post. In intervention practices
(n = 2), eligible patients were invited to attend the INCLUDE review. Outcome measures included health-related
quality of life (EQ-5D-5L), patient activation, self-efficacy and treatment burden. A sample (n = 24) of INCLUDE
review consultations were audio-recorded and assessed against a fidelity checklist.
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Results: 453/789 (57%) patients responded to the invitation, although 114/453 (25%) were excluded as they either
did not fulfil eligibility criteria or failed to provide full written consent. In the intervention practices, uptake of the
INCLUDE review was high at 72%. Retention at 3 and 6months both reached pre-specified success criteria.
Participants in intervention practices had more primary care contacts than controls (mean 29 vs 22) over the 12
months, with higher prescribing of all relevant medication classes in participants in intervention practices,
particularly so for osteoporosis medication (baseline 29% vs 12 month 46%). The intervention was delivered with
fidelity, although potential areas for improvement were identified.
Conclusions: The findings of this pilot study suggest it is feasible to deliver an RCT of the nurse-led integrated care
(INCLUDE) review in primary care. A significant morbidity burden was identified. Early results suggest the INCLUDE
review was associated with changes in practice. Lessons have been learnt around Read codes for patient
identification and refining the nurse training.
Trial registration: ISRCTN, ISRCTN12765345
Keywords: Integrated care, Multimorbidity, Comorbidity, Inflammatory rheumatological conditions, Anxiety,
Depression, Cardiovascular disease, Osteoporosis, Long-term conditions
Key messages regarding feasibility
 We were uncertain whether it would be possible to
identify patients with inflammatory conditions from
primary care records and whether patients with
these conditions would attend a nurse-led review.
 More patients than anticipated were identified using
primary care records. We found that some patients
identified using ankylosing spondylitis Read codes
did not report having the condition and a narrower
range of codes should be used in any future study.
 It was feasible to recruit and retain patients within
the study. Lessons have been learnt around Read
codes, refining the nurse training (informed by the
fidelity checking), especially around provision of
lifestyle advice and the meaning of the case-finding
questions for anxiety and depression.
Background
People with inflammatory rheumatological conditions
(IRCs), including rheumatoid arthritis (RA), psoriatic
arthritis (PsA), ankylosing spondylitis (AS), polymyalgia
rheumatica (PMR) and giant cell arteritis (GCA), are at
an increased risk of common comorbidities such as car-
diovascular disease (CVD), osteoporosis and depression
[1–6], leading to increased morbidity and mortality. This
is likely to be due to a combination of lifestyle factors
(such as smoking and limited physical activity) plus fac-
tors associated with the disease physiology and its treat-
ment. Currently, the identification and management of
these comorbidities is fragmented across primary and
secondary care, resulting in duplication of some screen-
ing or case-finding, such as CVD risk assessment (lead-
ing to an inefficient use of resources) [7], whilst other
comorbidities (including mood disorders) often remain
unrecognised and untreated [8], which has a negative
impact on patient outcomes [3, 4]. Data suggests that in
patients with RA, these comorbidities are often more se-
vere, but less well managed than in other populations
[9]. The National Institute for Health and Care Excel-
lence (NICE) RA guideline advocates an annual review
to include assessment of comorbidities [10], although
similar guidance does not exist for other inflammatory
conditions. For patients with RA, an annual review is
incentivised in the Quality and Outcomes Framework
[11]; however, the content of this is not specified, mean-
ing important comorbidities could be missed.
Evidence suggests that nurse-delivered reviews are an
effective mechanism to identify and manage comorbidity
in inflammatory conditions [12] and such an approach
reveals a high burden of undiagnosed morbidity [13].
Our hypothesis was that delivering an innovative nurse-
led review consultation in primary care could improve
patient outcomes and be cost-effective by enabling earl-
ier identification, intervention and management of com-
mon comorbidities in people with IRCs. Before testing
this new model of care in a definitive trial, we aimed to
determine the feasibility and acceptability of this new ap-
proach in a two-arm cluster pilot randomised controlled
trial (RCT).
Aims and objectives
The aim of this study was to assess the feasibility of con-
ducting a definitive cluster RCT of a nurse-led holistic
integrated care review for people with IRCs in primary
care. The primary objectives for this pilot study were as
follows:
1. To assess the overall engagement, recruitment and
study retention rates of both general practices and
participants.
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2. To evaluate the intervention uptake and delivery via
completion rates of the INCLUDE computer
template and the self-reported outcome measures.
3. To assess the fidelity of the intervention delivery by
study nurses.
4. To evaluate the acceptability of the integrated care
review from the perspectives of practitioners and
patients.
The secondary objective was to estimate the variability
of key outcomes (as listed in the “Questionnaire out-
come measures” section below) to potentially aid in esti-
mation of the sample size and resources required for a
future definitive RCT.
Methods
The study protocol has been published previously [14].
Brief methods for the pilot study are summarised below.
Recruitment and randomisation
Practice recruitment and sample size
As this was a pilot trial, a formal sample size calculation
was not required. The initial recruitment target was 100
adults per treatment arm, to ensure that the full range of
inflammatory conditions was represented. To achieve
this desired final sample size, we estimated that 200 pa-
tients would need to be invited per arm, allowing for ap-
proximately 50% (n = 100) consenting to participate.
Previous work using the Consultation in Primary Care
Archive (CiPCA) database of primary care medical re-
cords suggested that a “typical” general practice with 10,
000 patients will have 25, 20, 3 and 4 patients registered
with RA, PMR, AS and PsA respectively per year (GCA
numbers were not available) [15]. We estimated there-
fore that between two and six GP practices per arm (de-
pending on practice size and demographics) would be
required. Stratified block randomisation was used; strati-
fication was performed by practice size (splitting by
order of highest/lowest practice sizes) and block sizes of
2 and/or 4 used within each stratum to ensure balanced
cluster and individual patient numbers across treatment
arms.
Patient recruitment
Practice staff identified an initial list of patients aged 18
years and older who had a diagnostic Read code (a UK
coded thesaurus of clinical terms which provide a stan-
dardised way of recording diagnoses) for one of the 5
IRCs of interest [rheumatoid arthritis (RA), psoriatic
arthritis (PsA), ankylosing spondylitis (AS), polymyalgia
rheumatica (PMR) and/or giant cell arteritis (GCA)] in
their primary care records. A general practitioner (GP)
in each practice reviewed the list for exclusions (e.g. ter-
minal illness, living in nursing home: a full list of
inclusions/exclusions is contained within the protocol
paper [14]). Patients were mailed a study baseline pack
including a Patient Information Sheet and Baseline
Questionnaire with consent form. Reminder postcards were
sent after 2 weeks and a reminder invitation pack sent after
4 weeks to non-responders. Patients not responding after 4
weeks were considered non-responders. Participants who
consented at baseline but did not report having one of the
conditions of interest were deemed ineligible for the study
and excluded (this appeared to be a particular problem for
Read codes for AS; see the “Lessons learnt” section). Pa-
tients who did not complete the consent form fully were
sent a second letter to confirm missing details—if this was
not received after 1 month, the patients were considered in-
eligible responders and excluded. The study was approved
by the Wales REC 5 Research Ethics Committee (REC ref-
erence 17/WA/0427). All participants provided written in-
formed consent.
Study procedures
Responders were sent postal follow-up questionnaires at
3 months and 6months, with reminder mailings follow-
ing the same procedure as at baseline. All participants
(in both intervention and control arms) received usual
GP care for the duration of the study. In consenting par-
ticipants, medical record review to assess the extent of
primary care use was undertaken at 12 months. This was
defined as the sum of primary care contacts, which
could include face-to-face and telephone consultations,
or scanned letters and test results (with several contacts
from 1 day counting as a single contact). Furthermore, a
rheumatology consultant (lead author SH) reviewed the
prescribing records of medications used by participants
in this period, a subset of which was subsequently
grouped into lipid lowering, antihypertensives, treat-
ments for osteoporosis and antidepressants.
Questionnaire outcome measures
Full details of the questionnaire measures included are
detailed in the protocol paper [14]. Key domains in-
cluded health-related quality of life (EQ-5D-5L) [16, 17],
anxiety (using the Generalised Anxiety Disorder Ques-
tionnaire (GAD-7)) [18], depression (using the Patient
Health Questionnaire PHQ-8) [19, 20], Patient Activa-
tion (PAM) [21], Multimorbidity Treatment Burden
(MTBQ) [22] and self-efficacy (Self-Efficacy for Man-
aging Chronic Disease) [23]. Items also measured at
follow-up included treatment acceptability and credibil-
ity [24], patient satisfaction (using the General Practice
Assessment Questionnaire (GPAQ)) [25] and healthcare
utilisation. Unfortunately, we were unable to obtain ag-
gregated PAM results from Insignia health and therefore
are unable to report these results.
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Control arm
Control participants received usual GP care for the dur-
ation of the study.
Intervention arm
Consenting patients from intervention practices were
mailed an INCLUDE intervention appointment letter,
giving details of the INCLUDE review appointment at
their GP practice (with the option to telephone to re-
arrange the appointment as required). A reminder tele-
phone call was made approximately 48 h prior to the
appointment.
The INCLUDE review
The content of the INCLUDE review was developed
with patients (at two patient advisory groups) and practi-
tioners, and was designed to be a holistic consultation to
include case-finding and identification and initial man-
agement of CVD (using QRISK2) [26], obesity (assessing
body mass index (BMI)), fracture risk (using FRAX)
[27], anxiety and depression (using GAD2 and PHQ-2
with full measures (GAD-7 and PHQ-9) used when ap-
propriate) [18–20]. The consultation was recorded by
the specialist nurse delivering the INCLUDE review
using a study-specific EMIS computer template (the IN-
CLUDE template), which was then saved as part of the
patient’s clinical care record within EMIS at the GP
study general practice, and then de-identified and se-
curely transferred for analysis. As part of the study tem-
plate, an individualised management plan was agreed
with the patient who was provided with a summary
sheet at the end of the review for information. A sample
of INCLUDE reviews were digitally recorded, following
consent obtained by a study researcher prior to the re-
view consultation.
Nurse training
The nurses delivering the review (N = 2) (who had back-
grounds in rheumatology and research) participated in
an evidence-based training package delivered over two
and a half days, which was designed by clinicians with
input from the patient advisory group, to equip them to
deliver the review. The training was delivered by mem-
bers of the research team (CCG and AM). This involved
the use of written materials, a slide-set, role play using
simulated patients and training to use the GP software
system EMIS and the INCLUDE template.
Process evaluation
A random sample of consultations were digitally re-
corded (n = 24). These were listened to by members of
the research team and scored against a pre-specified fi-
delity checklist, developed by the research team (AM,
CCG, EE) (for full checklist, see supplementary table),
ensuring that key components of the intervention
(around purpose of consultation, physical health mea-
sures, cardiovascular risk, fracture risk, mood and sign-
posting for follow-up) had been covered within the
consultation. In addition, as part of a mixed methods
process evaluation to examine the acceptability of the in-
tegrated care review from the perspectives of practi-
tioners and patients participating in the review, a nested
qualitative interview study was conducted and is re-
ported separately [28].
Pilot trial success criteria
We pre-specified a series of criteria to define the success
of the pilot trial using criteria adapted from Avery et al.
[29], following discussion with the TSC. To fully assess
the impact of the INCLUDE intervention, we pre-
specified a high retention rate as being key to inform the
feasibility and economics of any future large-scale trial.
Given that patients were identified in an efficient man-
ner using GP records, it was decided a priori that an up-
take rate of 50% would be acceptable. These were based
on a Red Amber Green (RAG) rating system and per-
tained to the following:
1. Response rates: participant response
Red—Uptake < 25% of eligible patients
Amber—Uptake 25–50% of eligible patients
Green—Uptake > 50% of eligible patients
2. Retention rates (at 3 and 6 months)
Red—Follow-up rate < 50%
Amber—Follow-up rate 50–70%
Green—Follow-up rate > 70%
3. Intervention uptake rates (i.e. uptake from





As a pilot study, analysis was exploratory, focused upon
process outcomes. Descriptive statistics were used to
summarise patient eligibility, recruitment, intervention
uptake and retention in the follow-up, overall and strati-
fied by study arm. Self-reported baseline patient data are
also summarised by study arm; continuous data were
summarised via means and standard deviations or me-
dian and interquartile range, depending on data skew-
ness. We estimated means and medians, as appropriate,
and associated 95% confidence intervals and interquar-
tile range (IQR) for change between 3 months and 6
months and baseline for each outcome measure, by
study arm to determine which outcomes were most sen-
sitive to change over time. Variance component random
effects models were used to estimate a range of practice-
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level intra-cluster correlation coefficients (ICCs), meas-
uring proportion of the individual variance attributable
to cluster membership, in order to help inform the sam-
ple size calculation for a definitive trial.
Medical records of consenting participants were
reviewed for the period between baseline and 12 months
follow-up, to assess extent of primary care use. Prescrip-
tions within the first 90 days were considered as baseline
Fig. 1 Study participant flowchart
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Table 3 Baseline patient characteristics
All (333) Control (170) Intervention (163)
N (%) unless otherwise stated
Socio-demographic
Age, mean (SD) 68.2 (13.4) 67.7 (13.2) 68.6 (13.6)
Gender, female 200 (60) 100 (60) 100 (60)
Ethnicity, white 319 (96) 165 (97) 154 (94)
Employment status
Employed 68 (20) 31 (18) 37 (23)
Retired 197 (59) 97 (57) 100 (61)
Too ill to work 16 (5) 12 (7) 4 (2)
Unemployed/housewife/househusband 23 (7) 13 (8) 10 (6)
Lifestyle
Ever smoked 164 (49) 80 (47) 84 (52)
Alcohol consumption
Daily/3–4 times per week 84 (25) 42 (25) 42 (26)
Once a week/few times per month 116 (35) 60 (35) 56 (34)
Never/special occasions 119 (36) 61 (36) 58 (36)
BMI; mean (SD) 26.7 (7.2) 27.3 (7.1) 26.1 (7.3)
BMI ≥ 25 218 (65) 111 (65) 107 (66)
Inflammatory conditions
RA 172 (52) 91 (54) 81 (50)
AS 53 (16) 33 (19) 20 (12)
PsA 46 (14) 23 (14) 23 (14)
PMR 88 (26) 44 (26) 44 (27)
GCA 17 (5) 2 (1) 15 (9)
More than one inflammatory condition 35 (11) 20 (12) 15 (9)
Self-reported health conditions
Diabetes 52 (16) 26 (15) 26 (16)
Angina 24 (7) 13 (8) 11 (7)
High blood pressure 154 (46) 80 (47) 74 (45)
Heart attack 25 (8) 13 (8) 12 (7)
Stroke 18 (5) 11 (6) 7 (4)
Depression/anxiety 70 (21) 38 (22) 32 (20)
Osteoporosis 37 (11) 16 (9) 21 (13)
General health rating
Excellent/very good 43 (13) 20 (12) 23 (14)
Good 128 (38) 66 (39) 62 (38)
Fair/poor 154 (46) 78 (46) 76 (47)
Outcome measures
Current symptoms from inflammatory condition
Pain (0–10 NRS), mean (SD) (n = 327) 4.9 (2.6) 5.1 (2.7) 4.7 (2.6)
Stiffness (0–10 NRS), mean (SD) (n = 326) 5.0 (2.6) 5.4 (2.7) 4.7 (2.5)
Fatigue (0–10 NRS), mean (SD) (n = 324) 5.2 (2.7) 5.4 (2.7) 5.0 (2.8)
Self-Efficacy for Managing Chronic Diseasea, mean (SD) (n = 330) 5.98 (2.52) 5.83 (2.52) 5.98 (2.52)
General health rating
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Table 3 Baseline patient characteristics (Continued)
All (333) Control (170) Intervention (163)
N (%) unless otherwise stated
Excellent/very good 43 (13) 20 (12) 23 (14)
Good 128 (38) 66 (39) 62 (38)
Fair/poor 154 (46) 78 (46) 76 (47)
EQ-5Db mobility
No problems walking 86 (25) 41 (24) 45 (27)
Slight problems walking 99 (30) 49 (29) 50 (31)
Moderate problems walking 106 (32) 57 (33) 49 (30)
Severe problems walking 36 (11) 19 (11) 17 (10)
Unable to walk 2 (1) 1 (1) 1 (1)
Missing 4 (1) 3 (2) 1 (1)
EQ-5D self-care
No problems washing/dressing 196 (59) 98 (58) 98 (60)
Slight problems washing/dressing 68 (20) 31 (18) 37 (23)
Moderate problems washing/dressing 51 (15) 29 (17) 22 (13)
Severe problems washing/dressing 9 (3) 6 (3) 3 (2)
Unable to wash/dress 3 (1) 1 (1) 2 (1)
EQ-5D usual activities
No problems doing usual activities 62 (19) 28 (16) 24 (21)
Slight problems doing usual activities 111 (33) 61 (36) 50 (30)
Moderate problems doing usual activities 108 (33) 51 (30) 57 (35)
Severe problems doing usual activities 37 (11) 22 (13) 15 (9)
Unable to doing usual activities 11 (3) 5 (3) 6 (4)
EQ-5D pain
No pain/discomfort 116 (35) 61 (36) 55 (34)
Slight problems pain/discomfort 134 (40) 65 (39) 69 (42)
Moderate problems pain/discomfort 55 (16) 31 (18) 24 (15)
Severe problems pain/discomfort 4 (1) 2 (1) 2 (1)
Extreme pain/discomfort 5 (2) 4 (2) 1 (1)
EQ-5D anxiety/depression
Not anxious/depressed 150 (45) 79 (47) 71 (43)
Slightly anxious/depressed 111 (33) 55 (32) 56 (34)
Moderately anxious/depressed 57 (17) 28 (17) 29 (18)
Severely anxious/depressed 7 (2) 4 (2) 3 (2)
Extremely anxious/depressed 1 (1) 0 (0) 1 (1)
FACIT-Fatiguec, mean (SD) (n = 327) 33.1 (11,6) 33.5 (11.5) 32.7 (11.8)
Multimorbidity Treatment Burden Questionnaire (MTBQ)d
Median (IQR) 7.5 (2.5, 17.5) 7.5 (2.5, 17.5) 7.5 (2.5, 20)
No burden (score = 0) 72 (22) 37 (22) 35 (21)
Low burden (0 < score < 10) 104 (31) 53 (31) 51 (31)
Medium burden (10 ≥ score < 22) 86 (26) 48 (28) 38 (23)
High burden (22 ≥ score ≤ 100) 67 (20) 29 (17) 38 (23)
Modified Health Assessment Questionnaire (MHAQ)e
Mild (score ≤ 1.3) 308 (92) 156 (92) 152 (93)
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(to account for being prescribed medication up to 3
monthly) and compared with those seen at 12 months.
As this study was a feasibility study and not powered
to detect differences between arms, p values are not pre-
sented. All participants were analysed on a randomised




Twenty-eight general practices across the West Mid-
lands (North) Clinical Research Network region were in-
vited to participate in the INCLUDE study. Of those, 12
practices expressed interest in the study (43%), two prac-
tices declined to participate citing involvement in on-
going studies (7%) and 14 practices did not respond to
the original invitation to establish interest (50%). Interest
was gained from large general practices and there was
better than expected recruitment of trial participants to
the study, so only practices in randomisation block 1
were included—giving two intervention and two control
practices.
Participant recruitment and retention
Of the 839 people identified from the practice list
screening, 789 (94%) were deemed eligible by their GP
and were mailed a baseline study pack. Table 1 details
the number of people invited per practice, the response
rate and reasons why responders were deemed ineligible.
114/453 (25%) of responders had to be excluded as they
either (a) did not provide full written consent, (b) data
was missing for IRC or they did not report one of the
conditions of interest, or their eligibility based on age
could not be determined. The overall response RAG rat-
ing was Green at 57%. The overall study flow, consort
diagram and reasons for participant exclusion are de-
tailed in Fig. 1.
Table 2 illustrates the participant retention and par-
ticipation. Questionnaire response rates were Green in
both control (56%) and intervention practices (59%).
The overall RAG retention rates were over 70% (Green)
in all practices at both 3 and 6months, except one prac-
tice had RAG retention rate of Amber (69%) at 6
months. The RAG rating for intervention uptake was
Green (> 70%) in both practices. Of the 169 eligible re-
sponders in intervention practices, 129 completed the
INCLUDE nurse-led intervention (see Fig. 1 for the
breakdown). More patients than anticipated were identi-
fied with IRCs within each practice, and following dis-
cussion to ensure equity and a spread across conditions,
we invited all eligible patients within each practice,
meaning that we had more participants than anticipated.
Table 3 Baseline patient characteristics (Continued)
All (333) Control (170) Intervention (163)
N (%) unless otherwise stated
Moderate (1.3 < score ≤ 1.8) 16 (5) 6 (4) 10 (6)
Severe (score > 1.8) 5 (2) 5 (3) 0 (0)
GAD-7f
Mild anxiety (score 0–5) 208 (62) 110 (65) 98 (60)
Moderate anxiety (6–10) 75 (22) 39 (23) 36 (22)
Moderately severe anxiety (11–15) 36 (11) 16 (9) 20 (12)
Severe anxiety(16–21) 10 (3) 3 (2) 7 (4)
PHQ-8g
Insignificant depression (score 0–4) 176 (53) 92 (54) 84 (52)
Mild depression (5–9) 86 (26) 44 (26) 42 (26)
Moderate depression (10–14) 39 (12) 17 (10) 22 (13)
Moderately severe depression (15–19) 20 (6) 10 (6) 10 (6)
Severe depression (20–24) 10 (3) 6 (3) 4 (2)
aSelf-Efficacy for Managing Chronic Disease—composed of 6 items scored 0 (not confident at all) to 10 (totally confident): score calculated as mean of the six
items (at least 4 out of 6 items required); lower score indicates worse self-efficacy
bEQ-5D: higher score indicates worse health
cFACIT-Fatigue—composed of 13 items; scored as 4 = most positive response, 0 = most negative response. Total score calculated as mean of the 13 items (at
least 7 out of 13 items required); lower score indicates worse fatigue score
dMTBQ—10-item scale: score calculated as mean of the 10 items; higher score indicates worse multimorbidity burden
eMHAQ—composed of 8 items scored 0 (without any difficulty) to 3 (unable to do); final score is calculated as the mean of the eight items (at least 6 out of 8
items required); higher score indicates worse function
fGAD-7—composed of 7 items scored 0 to 3; score calculated as the total of the six items (score range 0–21); higher score indicates worse anxiety.
gPHQ-8—composed of 13 items scored 0–3; score calculated as the total of 13 items (score 0–24); higher score indicates worse depression
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Baseline characteristics and follow-up
Table 3 illustrates the baseline characteristics and out-
comes of the 333 participants that formed the study
sample, overall and stratified by study arm. The mean
(SD) age was 68.2 (13.4) years and 200/333 (60%) were
female. 319/333 (96%) of patients reported themselves
being of white ethnicity. Over half of the participants re-
ported being retired, and 164 (49%) reported ever smok-
ing and a quarter reported consuming alcohol on a daily
or almost daily basis. A total of 218 (65%) participants
self-reported being overweight (BMI ≥ 25). As was ex-
pected, the majority of patients reported either RA (172
(52%)) or PMR (88 (26%)) with 35 (11%) reporting more
than one IRC. Nearly half of the patients reported having
high blood pressure, and a fifth reported suffering from
depression or anxiety.
Eighty-six (26%) of the 333 participants were lost to ei-
ther 3-month or 6-month follow-up; there was modest
variation between the four practices: 21–34%, with con-
trol practices generally having lower loss to follow-up
(Table 2). Compared to the 247 participants that
responded at both 3- and 6-month follow-up time
points, these patients were slightly less likely to be fe-
male (58% vs 61%), were on average younger (mean 66
vs 69), but were notably more likely to be employed
(28% vs 18%) and less likely to report more than one
IRC (7% vs 12%).
Variability estimates for key outcomes
Table 4 illustrates the variability for the key outcomes
over follow-up and between treatment arms. With re-
gard to EQ-5D, MHAQ, GAD and PHQ scores, there
were both negligible differences between treatment arms
as well as change over time (this is also evident from
categorical formation of these measures as presented in
Table 3). Control participants reported slightly worse
scores of self-efficacy at baseline (mean 5.8 vs 6.0), but
by 6-month follow-up, mean score was the same in the
two treatment arms. Multimorbidity burden appeared to
be approximately the same in the control and interven-
tion arms at baseline (median 7.5 in both); however,
whilst the score remained constant over the follow-up
among the control participants, it considerably increased
among the intervention group (3- and 6-month median
= 10). Table 5 details the change in composition of GAD
and PHQ categories over time.
Intra-class correlation coefficient
The ICC was calculated using all outcome measures and
ranged between 0.003 and 0.04. These ICC estimates
however are likely to be imprecise and thus unreliable
due to a small number of clusters [30].
Assessment of the INCLUDE intervention
One hundred twenty-nine out of 169 intervention partic-
ipants attended the INCLUDE review. The reasons for
non-attendance for the remainder of the participants in-
cluded study withdrawal, inability to contact patient or
nurse absence due to sickness, among others (see Fig. 1).
The INCLUDE EMIS template was completed for all
129 patients, and the summary information sheet was
given to 124 (96%) patients (94% in intervention practice
A, 98% in intervention practice C). The recording of in-
dividual items, such as pulse, blood pressure, BMI,
smoking status and alcohol use, was high (97% overall,
94% in practice A, 100% in practice C).
Table 5 GAD and PHQ measures at baseline and follow-up
All Control Intervention
Baseline 6months Baseline 6months Baseline 6months
GAD-7
Mild anxiety (score 0–5) 208 (62) 173 (52) 110 (65) 93 (55) 98 (60) 80 (49)
Moderate anxiety (6–10) 75 (23) 56 (17) 39 (23) 33 (19) 36 (22) 23 (14)
Moderately severe anxiety (11–15) 36 (11) 21 (6) 16 (9) 10 (6) 20 (12) 11 (7)
Severe anxiety(16–21) 10 (3) 10 (3) 3 (2) 3 (2) 7 (5) 7 (4)
Missing 4 (1) 73 (22) 2 (1) 31 (18) 2 (1) 42 (26)
PHQ-8
Insignificant depression (score 0–4) 176 (53) 154 (46) 92 (54) 85 (50) 84 (52) 69 (42)
Mild depression (5–9) 86 (26) 57 (17) 44 (26) 31 (18) 42 (26) 26 (16)
Moderate depression (10–14) 39 (12) 25 (8) 17 (10) 8 (5) 22 (13) 17 (10)
Moderately severe depression (15–19) 20 (6) 15 (5) 10 (6) 10 (6) 10 (6) 5 (3)
Severe depression (20–24) 10 (3) 8 (2) 6 (3) 4 (2) 4 (2) 4 (2)
Missing 2 (1) 74 (22) 1 (1) 31 (19) 1 (1) 42 (26)
Hider et al. Pilot and Feasibility Studies             (2021) 7:9 Page 12 of 17
Table 6 Treatment acceptability and credibility, and patient satisfaction at 3 months (intervention arm only)
All participants that received





Treatment acceptability and credibilityb
How logical does the intervention offered to you seem? Mean (SD); (%
completed item)
6.3 (3.0); 76% 6.0 (3.0); 76% 6.5 (3.0); 76%
How successful do you think this intervention will be in improving your
health? Mean (SD); (% completed item)
5.3 (2.7); 76% 5.1 (2.8); 78% 5.5 (2.7); 75%
How confident would you be in recommending this intervention to a friend?
Mean (SD); (% completed item)
5 (3.3); 76% 5.2 (3.3); 78% 5.8 (3.4); 75%
How much improvement in your general health do you think will occur?
Mean (SD); (% completed item)
4.2 (3.1); 74% 4.0 (3.4); 76% 4.4 (2.9); 71%
GPAQ: at your recent INCLUDE review appointment, how good was the nurse at: N (%)
Putting you at ease?
Very good 65 (59) 29 (53) 36 (65)
Good 20 (18) 12 (22) 8 (15)
Satisfactory 5 (5) 5 (9) 1 (2)
Poor 0 0 0
Very poor 0 0 0
Missing 19 (17) 9 (16) 10 (18)
Giving you enough time?
Very good 59 (54) 27 (49) 32 (58)
Good 26 (24) 16 (29) 10 (18)
Satisfactory 5 (4) 2 (4) 3 (5)
Poor 1 (1) 1 (2) 0
Very poor 0 0 0
Missing 19 (17) 9 (16) 10 (18)
Listening to you
Very good 58 (53) 26 (47) 32 (58)
Good 24 (22) 14 (25) 10 (18)
Satisfactory 8 (7) 5 (9) 3 (5)
Poor 1 (1) 1 (2) 0 (0)
Very poor 0 0 0 (0)
Missing 19 (17) 9 (16) 10 (18)
Explaining your condition and treatment?
Very good 47 (43) 20 (36) 27 (49)
Good 27 (25) 15 (27) 12 (22)
Satisfactory 7 (6) 4 (7) 3 (5)
Poor 5 (4) 4 (7) 1 (2)
Very poor 0 0 0
Missing 24 (22) 12 (22) 12 (22)
Involving you in decisions about your care?
Very good 40 (36) 15 (27) 25 (45)
Good 30 (27) 17 (31) 13 (24)
Satisfactory 11 (10) 8 (15) 3 (5)
Poor 4 (4) 3 (5) 1 (2)
Very poor 0 0 0 (0)
Missing 25 (23) 12 (22) 13 (24)
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Fidelity checking
Whilst most components of the INCLUDE review were
delivered as intended in the sample (n = 24) of consulta-
tions recorded, there were some exceptions (Supplemen-
tary Table). Lifestyle advice about weight, diet, activity
and alcohol was not, however, always optimally given. In
addition, verbal advice was not always backed up with
leaflets. There was one example of confusion over FRAX
scores, with a calculation being done when a patient was
already taking a bisphosphonate, and signposting to the
GP not done in one person with a high FRAX score.
The meaning of the case-finding questions for anxiety
and depression was not always conveyed to the partici-
pants fully, but when PHQ-9 and GAD-7 were con-
ducted, the nurses did explain the meaning of the
scores. Whilst the written INCLUDE summary sheet
was given to patients at the end of each of the recorded
reviews, the nurses did not always ask study participants
if they had any questions, or respond optimally to quer-
ies from patients.
Of the 129 participants who received the interven-
tion, 110 returned the 3-month questionnaire, and
therefore, treatment acceptability and credibility, as
well as patient satisfaction, at 3 months could be mea-
sured for these patients (Table 6). Completion rates for
majority of these items were around 75%, which was
lower than anticipated. The results identify areas where
more attention and emphasis are needed in the train-
ing. For example, mean scores were lower for the ques-
tion that asks “How much improvement in your
general health do you think will occur?” This question
closely aligns with our hypothesis that patient out-
comes can be improved through earlier identification,
intervention and management of common comorbidi-
ties in people with inflammatory rheumatological
conditions (IRCs).
Medical record review
Two hundred ninety-nine of 333 participants consented
to full medical record review (Table 7). The mean num-
ber of primary care contacts in the period between base-
line and 12-month follow-up was 25 (SD 15).
Participants in intervention practices had more primary
care contacts (mean 29 vs 22). Over the 12-month
follow-up, participants in intervention practices were
more likely to be prescribed lipid lowering drugs (51% vs
47%), osteoporosis drugs (46% vs 28%) and antidepres-
sants (25% vs 22%). These observations were less marked
in the first 90 days following baseline. A higher propor-
tion of control than intervention participants were pre-
scribed antihypertensive drugs, a finding that was
particularly noted in the first 90 days post-baseline (54%
vs 46%).
Feasibility criteria
Tables 1 and 2 highlight the results of the pre-specified
feasibility criteria. These highlight that the recruitment
rates overall reached the Green RAG rating, at 50%. The
uptake rates from invitation to nurse-led review in the
intervention arm were high at > 70%. The retention rates
in the study overall also reached the specified RAG rat-
ing of 50%.
Discussion
The INCLUDE study was designed to assess the feasibil-
ity of running a definitive cluster RCT of a nurse-led
holistic integrated care review for people with IRCs in
primary care. Findings presented here show that the
study met its pre-specified success criteria, and hence, it
is feasible to deliver a trial of this nature within this
population. The recruitment strategy of screening GP re-
cords for Read codes of IRCs was successful at identify-
ing a sample of patients who met the eligibility criteria,
Table 6 Treatment acceptability and credibility, and patient satisfaction at 3 months (intervention arm only) (Continued)
All participants that received





Providing or arranging treatment for you?
Very good 39 (35) 14 (25) 25 (45)
Good 26 (24) 14 (25) 12 (22)
Satisfactory 10 (9) 8 (14) 2 (4)
Poor 5 (4) 3 (5) 2 (4)
Very poor 0 0 0
Missing 30 (27) 16 (29) 14 (25)
Would you be completely happy to see this nurse again?
Yes 81 (74) 39 (71) 42 (76
No 6 (5) 4 (7) 2 (4)
Missing 23 (21) 12 (22) 11 (20)
a128 participants received intervention, 110 of these completed 3 months questionnaire
bAll four items are scored as 0 (least) to 10 (most) numerical rating scale
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although the Read codes seemed to over-include patients
with AS and lessons have been learnt for future work.
The outcome measures were collected successfully at
baseline and follow-up, and the INCLUDE intervention
and study-specific EMIS template was feasible to use in
primary care practice. The intervention was delivered as
intended, with most of the components of the interven-
tion delivered with excellent fidelity.
Baseline data showed there was a high burden of self-
reported multimorbidity in this population. Whilst there
were no major changes between intervention and con-
trol practices in the questionnaire outcome measures
(although the pilot study was not powered to be able to
assess significant differences between groups), there did
appear to be differences between the intervention and
control patients. Firstly, the self-reported treatment bur-
den was higher in the intervention participants at
follow-up, suggesting that additional morbidities were
identified and management suggested. Furthermore,
practices undertaking these reviews had higher prescrib-
ing rates at 12 months (especially of osteoporosis treat-
ments) following treatment of previously un-identified
conditions. This suggests that patients with IRCs would
benefit from an integrated care review to identify and
manage common morbidities.
Lessons learnt
The results of this pilot study showed that it was feasible
to deliver the nurse-led INCLUDE review intervention.
There are some limitations with the use of only four GP
practices. Whilst initial recruitment rates were excellent,
several participants did not report having one of the
conditions of interest and it may be that a more strin-
gent/different Read code strategy for inclusion (espe-
cially around Read codes for ankylosing spondylitis, AS)
would have been of benefit. However, retention rates
were excellent at 3 and 6months.
In terms of intervention delivery and fidelity, analysis
of the consultation audio-recordings suggested that con-
sultations were delivered by adhering strictly to the tem-
plate which sometimes limited explanations of findings,
especially around bone health and the use of FRAX. The
consultations did not always appear to be patient-
centred. These findings have identified where modifica-
tions are needed in the training for future interventions.
Acceptability of the INCLUDE review has been inves-
tigated in a qualitative interview study (reported else-
where). We are using the results of the feasibility trial
reported here and qualitative study to determine next
steps for the INCLUDE review.
Conclusions
We conclude that it is feasible and practical to deliver a
cluster RCT of a nurse-led, holistic, integrated care re-
view for people with IRCs in primary care. Given the im-
pact of managing people with multiple long-term
conditions and the comorbidity burden associated with
IRCs, such an approach has the potential to improve
care and hence morbidity and mortality in this patient
group.
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